Lukashevich Igor S, Paessler Slobodan, de la Torre Juan Carlos
Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, 40292, USA.
Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, 77555, USA.
F1000Res. 2019 Jan 31;8. doi: 10.12688/f1000research.16989.1. eCollection 2019.
Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, , which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO's TPP for an LASV vaccine.
拉沙病毒（LASV）是西非一种高度流行的沙粒病毒，在自然界中由持续感染的啮齿动物宿主维持传播，该宿主在撒哈拉以南非洲广泛分布。人类感染拉沙病毒可引发拉沙热（LF），这是一种发病率高且死亡率显著的疾病。最近的证据表明拉沙病毒在其传统流行地区之外有所扩张。2017年，世界卫生组织（WHO）将拉沙病毒列入高度优先病原体，并发布了疫苗研发的目标产品概况（TPP）。同样，2018年，美国食品药品监督管理局将拉沙热纳入优先审评券计划，以鼓励开发预防和治疗措施。在本文中，我们回顾拉沙病毒疫苗研发的最新进展，重点关注拉沙病毒的遗传和生物学多样性对符合WHO拉沙病毒疫苗TPP的候选疫苗设计和开发的影响。
